PLEKHA4

Across TCGA pan-cancer cohorts, PLEKHA4 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PLEKHA4 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PLEKHA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHA4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

THYM, SARC, and KIRC are the cancer types where PLEKHA4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
KIRC	OS	Median	All	0.140	0.628	.038	6	view →
ESCA	DFS	Median	II,III,IV	0.228	0.527	.023	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
LIHC	OS	Median	All	0.258	0.690	.024	6	view →
UCEC	DFS	Median	All	0.962	0.627	.027	6	view →
KIRP	DFS	Median	All	0.133	0.605	.014	3	view →
COAD	DFS	Median	All	0.917	0.495	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PLEKHA4–THYM (OS)

Open the THYM breakdown →